Sarepta Therapeutics, Inc. (SRPT)
USD 54.87
(-6.39%)
USD 54.87
(-6.39%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.26 Billion USD | 4.35% |
| 2022 | 3.12 Billion USD | -0.62% |
| 2021 | 3.14 Billion USD | 5.47% |
| 2020 | 2.98 Billion USD | 63.74% |
| 2019 | 1.82 Billion USD | 11.01% |
| 2018 | 1.64 Billion USD | 25.54% |
| 2017 | 1.3 Billion USD | 208.41% |
| 2016 | 424.1 Million USD | 54.91% |
| 2015 | 273.78 Million USD | -7.2% |
| 2014 | 295.03 Million USD | 1.19% |
| 2013 | 291.56 Million USD | 42.23% |
| 2012 | 204.99 Million USD | 277.05% |
| 2011 | 54.36 Million USD | 18.25% |
| 2010 | 45.97 Million USD | -23.41% |
| 2009 | 60.02 Million USD | 135.07% |
| 2008 | 25.53 Million USD | -33.91% |
| 2007 | 38.63 Million USD | -5.44% |
| 2006 | 40.86 Million USD | -27.56% |
| 2005 | 56.4 Million USD | 97.79% |
| 2004 | 28.51 Million USD | -39.51% |
| 2003 | 47.14 Million USD | 64.82% |
| 2002 | 28.6 Million USD | -15.41% |
| 2001 | 33.81 Million USD | -3.63% |
| 2000 | 35.08 Million USD | 172.0% |
| 1999 | 12.9 Million USD | 26.47% |
| 1998 | 10.2 Million USD | -45.74% |
| 1997 | 18.8 Million USD | 347.62% |
| 1996 | 4.2 Million USD | 82.61% |
| 1995 | 2.3 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.22 Billion USD | -1.23% |
| 2024 Q2 | 3.42 Billion USD | 6.2% |
| 2023 Q2 | 3.12 Billion USD | 2.16% |
| 2023 FY | 3.26 Billion USD | 4.35% |
| 2023 Q4 | 3.26 Billion USD | 4.98% |
| 2023 Q1 | 3.05 Billion USD | -2.19% |
| 2023 Q3 | 3.1 Billion USD | -0.52% |
| 2022 Q1 | 3.05 Billion USD | -2.92% |
| 2022 Q2 | 2.99 Billion USD | -1.94% |
| 2022 Q3 | 3.15 Billion USD | 5.32% |
| 2022 Q4 | 3.12 Billion USD | -0.88% |
| 2022 FY | 3.12 Billion USD | -0.62% |
| 2021 Q1 | 2.76 Billion USD | -7.35% |
| 2021 FY | 3.14 Billion USD | 5.47% |
| 2021 Q2 | 2.75 Billion USD | -0.22% |
| 2021 Q3 | 2.66 Billion USD | -3.51% |
| 2021 Q4 | 3.14 Billion USD | 18.25% |
| 2020 Q3 | 2.78 Billion USD | -3.55% |
| 2020 FY | 2.98 Billion USD | 63.74% |
| 2020 Q1 | 2.94 Billion USD | 61.69% |
| 2020 Q2 | 2.88 Billion USD | -2.18% |
| 2020 Q4 | 2.98 Billion USD | 7.34% |
| 2019 Q3 | 1.7 Billion USD | -2.59% |
| 2019 Q2 | 1.74 Billion USD | -11.01% |
| 2019 Q1 | 1.96 Billion USD | 19.6% |
| 2019 Q4 | 1.82 Billion USD | 7.07% |
| 2019 FY | 1.82 Billion USD | 11.01% |
| 2018 Q4 | 1.64 Billion USD | 38.82% |
| 2018 Q2 | 1.24 Billion USD | -4.09% |
| 2018 FY | 1.64 Billion USD | 25.54% |
| 2018 Q3 | 1.18 Billion USD | -5.15% |
| 2018 Q1 | 1.3 Billion USD | -0.59% |
| 2017 Q4 | 1.3 Billion USD | 63.44% |
| 2017 Q2 | 450.13 Million USD | -12.0% |
| 2017 Q3 | 800.28 Million USD | 77.79% |
| 2017 Q1 | 511.53 Million USD | 20.61% |
| 2017 FY | 1.3 Billion USD | 208.41% |
| 2016 Q4 | 424.1 Million USD | -12.97% |
| 2016 Q2 | 204.06 Million USD | -4.36% |
| 2016 Q3 | 487.31 Million USD | 138.8% |
| 2016 Q1 | 213.36 Million USD | -22.07% |
| 2016 FY | 424.1 Million USD | 54.91% |
| 2015 Q4 | 273.78 Million USD | 48.19% |
| 2015 Q3 | 184.75 Million USD | -20.27% |
| 2015 Q2 | 231.71 Million USD | -4.53% |
| 2015 Q1 | 242.7 Million USD | -17.74% |
| 2015 FY | 273.78 Million USD | -7.2% |
| 2014 Q2 | 337.3 Million USD | 22.48% |
| 2014 Q4 | 295.03 Million USD | -7.53% |
| 2014 FY | 295.03 Million USD | 1.19% |
| 2014 Q1 | 275.38 Million USD | -5.55% |
| 2014 Q3 | 319.05 Million USD | -5.41% |
| 2013 Q4 | 291.56 Million USD | -4.24% |
| 2013 FY | 291.56 Million USD | 42.23% |
| 2013 Q3 | 304.47 Million USD | 65.81% |
| 2013 Q2 | 183.63 Million USD | -5.02% |
| 2013 Q1 | 193.34 Million USD | -5.68% |
| 2012 FY | 204.99 Million USD | 277.05% |
| 2012 Q1 | 46.64 Million USD | -14.2% |
| 2012 Q3 | 53.08 Million USD | 26.08% |
| 2012 Q4 | 204.99 Million USD | 286.18% |
| 2012 Q2 | 42.1 Million USD | -9.75% |
| 2011 FY | 54.36 Million USD | 18.25% |
| 2011 Q2 | 74.93 Million USD | 59.33% |
| 2011 Q3 | 61.08 Million USD | -18.48% |
| 2011 Q4 | 54.36 Million USD | -10.99% |
| 2011 Q1 | 47.03 Million USD | 2.29% |
| 2010 Q3 | 50.86 Million USD | 4.51% |
| 2010 Q4 | 45.97 Million USD | -9.6% |
| 2010 FY | 45.97 Million USD | -23.41% |
| 2010 Q1 | 52.82 Million USD | -12.0% |
| 2010 Q2 | 48.66 Million USD | -7.87% |
| 2009 Q2 | 32.61 Million USD | -11.89% |
| 2009 FY | 60.02 Million USD | 135.07% |
| 2009 Q1 | 37.01 Million USD | 44.96% |
| 2009 Q4 | 60.02 Million USD | -7.83% |
| 2009 Q3 | 65.12 Million USD | 99.66% |
| 2008 Q4 | 25.53 Million USD | -13.48% |
| 2008 Q1 | 35.47 Million USD | -8.17% |
| 2008 FY | 25.53 Million USD | -33.91% |
| 2008 Q2 | 32.57 Million USD | -8.18% |
| 2008 Q3 | 29.51 Million USD | -9.4% |
| 2007 FY | 38.63 Million USD | -5.44% |
| 2007 Q4 | 38.63 Million USD | 43.82% |
| 2007 Q3 | 26.86 Million USD | -13.92% |
| 2007 Q1 | 35.3 Million USD | -13.6% |
| 2007 Q2 | 31.2 Million USD | -11.61% |
| 2006 Q4 | 40.86 Million USD | -12.2% |
| 2006 Q1 | 58.11 Million USD | 3.03% |
| 2006 Q3 | 46.54 Million USD | -11.15% |
| 2006 FY | 40.86 Million USD | -27.56% |
| 2006 Q2 | 52.38 Million USD | -9.87% |
| 2005 Q4 | 56.4 Million USD | 42.75% |
| 2005 Q3 | 39.51 Million USD | -2.53% |
| 2005 Q2 | 40.54 Million USD | -11.28% |
| 2005 Q1 | 45.69 Million USD | 60.24% |
| 2005 FY | 56.4 Million USD | 97.79% |
| 2004 FY | 28.51 Million USD | -39.51% |
| 2004 Q4 | 28.51 Million USD | -11.91% |
| 2004 Q3 | 32.37 Million USD | -15.12% |
| 2004 Q2 | 38.14 Million USD | -16.72% |
| 2004 Q1 | 45.8 Million USD | -2.85% |
| 2003 Q3 | 37.11 Million USD | -6.33% |
| 2003 Q2 | 39.62 Million USD | 85.74% |
| 2003 Q1 | 21.33 Million USD | -25.42% |
| 2003 FY | 47.14 Million USD | 64.82% |
| 2003 Q4 | 47.14 Million USD | 27.02% |
| 2002 FY | 28.6 Million USD | -15.41% |
| 2002 Q3 | 30.74 Million USD | -18.09% |
| 2002 Q4 | 28.6 Million USD | -6.96% |
| 2002 Q2 | 37.53 Million USD | -16.85% |
| 2002 Q1 | 45.13 Million USD | 33.48% |
| 2001 Q2 | 39.37 Million USD | 29.28% |
| 2001 Q3 | 33.14 Million USD | -15.83% |
| 2001 Q4 | 33.81 Million USD | 2.04% |
| 2001 FY | 33.81 Million USD | -3.63% |
| 2001 Q1 | 30.45 Million USD | -13.2% |
| 2000 Q1 | 15.79 Million USD | 22.41% |
| 2000 Q3 | 40.01 Million USD | 222.0% |
| 2000 Q4 | 35.08 Million USD | -12.31% |
| 2000 FY | 35.08 Million USD | 172.0% |
| 2000 Q2 | 12.42 Million USD | -21.31% |
| 1999 Q3 | 3.8 Million USD | -33.33% |
| 1999 FY | 12.9 Million USD | 26.47% |
| 1999 Q1 | 8 Million USD | -21.57% |
| 1999 Q2 | 5.7 Million USD | -28.75% |
| 1999 Q4 | 12.9 Million USD | 239.47% |
| 1998 Q4 | 10.2 Million USD | -19.05% |
| 1998 Q3 | 12.6 Million USD | -20.25% |
| 1998 Q1 | 17.5 Million USD | -6.91% |
| 1998 FY | 10.2 Million USD | -45.74% |
| 1998 Q2 | 15.8 Million USD | -9.71% |
| 1997 Q1 | 3.7 Million USD | -11.9% |
| 1997 Q4 | 18.8 Million USD | -3.09% |
| 1997 Q2 | 18.5 Million USD | 400.0% |
| 1997 Q3 | 19.4 Million USD | 4.86% |
| 1997 FY | 18.8 Million USD | 347.62% |
| 1996 Q4 | 4.2 Million USD | 0.0% |
| 1996 FY | 4.2 Million USD | 82.61% |
| 1995 FY | 2.3 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | -119.38% |
| Alkermes plc | 2.13 Billion USD | -52.82% |
| Agenus Inc. | 313.91 Million USD | -939.962% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 14.76% |
| Aptorum Group Limited | 20.64 Million USD | -15716.674% |
| Ardelyx, Inc. | 297.57 Million USD | -997.045% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -326.434% |
| Bicycle Therapeutics plc | 595.34 Million USD | -448.351% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -4329.427% |
| ChromaDex Corporation | 54.96 Million USD | -5839.48% |
| Chimerix, Inc. | 212.77 Million USD | -1434.293% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -11446.868% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -640.32% |
| CRISPR Therapeutics AG | 2.22 Billion USD | -46.422% |
| Precision BioSciences, Inc. | 159.78 Million USD | -1943.157% |
| Dyadic International, Inc. | 8.21 Million USD | -39618.728% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -10185.369% |
| Fortress Biotech, Inc. | 167.52 Million USD | -1848.698% |
| Lantern Pharma Inc. | 43.64 Million USD | -7379.391% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -1923.452% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -22404.001% |
| Incyte Corporation | 6.78 Billion USD | 51.865% |
| IO Biotech, Inc. | 150.71 Million USD | -2066.016% |
| Jaguar Health, Inc. | 50.76 Million USD | -6331.015% |
| Novavax, Inc. | 1.85 Billion USD | -75.955% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -758.18% |
| Opthea Limited | 188.79 Million USD | -1629.199% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -291.876% |
| ContextLogic Inc. | 423 Million USD | -671.767% |
| MiMedx Group, Inc. | 239.04 Million USD | -1265.663% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -1779.152% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -63048.256% |
| NextCure, Inc. | 129.41 Million USD | -2422.505% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -5951.338% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -8788.279% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -10006.734% |
| Vaxcyte, Inc. | 1.4 Billion USD | -131.873% |
| PDS Biotechnology Corporation | 59.39 Million USD | -5396.837% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -409.654% |
| Pharming Group N.V. | 462.85 Million USD | -605.314% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -8339.959% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -419.378% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -17151.279% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -17151.279% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -1874.701% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -7108.638% |
| Acelyrin, Inc. | 742.69 Million USD | -339.561% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -49464.482% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -50885.101% |
| Summit Therapeutics Inc. | 202.94 Million USD | -1508.57% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -4289.405% |
| Senti Biosciences, Inc. | 119.48 Million USD | -2632.229% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -1329.687% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -1841.189% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -39408.363% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -68285.728% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -595.787% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -2540.111% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -1087.339% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -590.419% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -32206.541% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -1421.904% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -288249.605% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -688.846% |
| Immix Biopharma, Inc. | 19.92 Million USD | -16284.19% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -782.258% |
| MEI Pharma, Inc. | 41.37 Million USD | -7790.214% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -9973.986% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -857.921% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -2684.88% |
| Fortress Biotech, Inc. | 167.52 Million USD | -1848.698% |
| Precigen, Inc. | 151.04 Million USD | -2061.355% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -9496.614% |
| AlloVir, Inc. | 190.79 Million USD | -1611.03% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -767.198% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -544.897% |
| ImmuCell Corporation | 43.8 Million USD | -7351.991% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -402.772% |
| Onconetix, Inc. | 88.82 Million USD | -3575.437% |
| PureTech Health plc | 693.97 Million USD | -370.418% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -3241.942% |
| Elevation Oncology, Inc. | 89.09 Million USD | -3564.316% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -52537.472% |
| Seer, Inc. | 436.26 Million USD | -648.294% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -3900.853% |
| Innoviva, Inc. | 1.24 Billion USD | -162.53% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -2365.264% |
| ESSA Pharma Inc. | 149.12 Million USD | -2089.196% |
| GlycoMimetics, Inc. | 45.31 Million USD | -7103.95% |
| GT Biopharma, Inc. | 14.1 Million USD | -23038.252% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -960.296% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -1250.656% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -591.784% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -6339.387% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -3328.744% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -516783.791% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -476.433% |
| Aptose Biosciences Inc. | 12.92 Million USD | -25162.642% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -14662.296% |
| Soligenix, Inc. | 9.79 Million USD | -33221.092% |
| Century Therapeutics, Inc. | 360.69 Million USD | -805.089% |
| Kura Oncology, Inc. | 448.93 Million USD | -627.182% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -1099.555% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -18775.837% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -2843.411% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -1491.304% |
| Autolus Therapeutics plc | 375.38 Million USD | -769.67% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -1197.341% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -819.122% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -6544.501% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -393.784% |
| GRI Bio, Inc. | 2.95 Million USD | -110338.972% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -30682.71% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -1814.539% |
| IGM Biosciences, Inc. | 423.41 Million USD | -671.018% |
| INmune Bio, Inc. | 57 Million USD | -5627.226% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -1367.186% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -3789.12% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -12399.88% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -47328.207% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -4239.691% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -2116.909% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -1872.506% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -418.513% |
| Verastem, Inc. | 149.71 Million USD | -2080.483% |
| Abeona Therapeutics Inc. | 64 Million USD | -5000.741% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -537.421% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -2013.582% |
| Histogen Inc. | 19.07 Million USD | -17016.217% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -14313.028% |
| Surrozen, Inc. | 46.08 Million USD | -6984.583% |
| Organovo Holdings, Inc. | 6.34 Million USD | -51318.743% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -75668.483% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -2166.645% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -27561.21% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -4237.269% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -38219.993% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -799.409% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -17941.917% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -660.261% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -25785.256% |
| Apollomics, Inc. | 55.38 Million USD | -5794.12% |
| Amarin Corporation plc | 831.68 Million USD | -292.526% |
| Mesoblast Limited | 669.15 Million USD | -387.867% |
| Turnstone Biologics Corp. | 112.81 Million USD | -2793.743% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -467.004% |
| Synaptogenix, Inc. | 31.11 Million USD | -10392.418% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -26693.959% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -495.658% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -55493.169% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -44345.273% |
| Exelixis, Inc. | 2.94 Billion USD | -10.951% |
| Better Therapeutics, Inc. | 22.94 Million USD | -14129.072% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -795.535% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -313.903% |
| NLS Pharmaceutics AG | 1.84 Million USD | -176684.551% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -40816.478% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -22115.556% |
| Gritstone bio, Inc. | 177.76 Million USD | -1736.415% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -3322.705% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -18176.378% |
| Avid Bioservices, Inc. | 336.55 Million USD | -869.992% |
| Insmed Incorporated | 1.32 Billion USD | -145.487% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -33805.889% |
| MediWound Ltd. | 66.45 Million USD | -4812.165% |
| OmniAb, Inc. | 401.98 Million USD | -712.114% |
| Alector, Inc. | 621.82 Million USD | -424.997% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -810.367% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -60602.417% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -5658.442% |
| Zai Lab Limited | 1.03 Billion USD | -215.024% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -582.318% |
| Aura Biosciences, Inc. | 255.07 Million USD | -1179.849% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -335.26% |
| Immunic, Inc. | 54.29 Million USD | -5912.221% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -1126.252% |
| Veracyte, Inc. | 1.13 Billion USD | -186.915% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -27512.587% |
| FibroGen, Inc. | 423.52 Million USD | -670.803% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -92828.437% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -68822.277% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -60026.885% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 71.347% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -36976.388% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -530.892% |
| TG Therapeutics, Inc. | 329.58 Million USD | -890.505% |
| Galecto, Inc. | 38.22 Million USD | -8439.974% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -11284.349% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 25.076% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -1286.797% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -13041.357% |
| XBiotech Inc. | 227.24 Million USD | -1336.601% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -3322.705% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -2189.324% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -1041.795% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -2453.063% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -754.603% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | -118.95% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -794.792% |
| Vaxxinity, Inc. | 44.35 Million USD | -7260.44% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -531.495% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -17442.683% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -970.177% |
| NexImmune, Inc. | 8.59 Million USD | -37886.914% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -30366.805% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -18960.556% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 90.131% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -14637.74% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -832137.391% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -1783.456% |
| Ainos, Inc. | 31.84 Million USD | -10152.484% |
| Pluri Inc. | 39.52 Million USD | -8159.104% |
| Prothena Corporation plc | 696.38 Million USD | -368.791% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -1055.128% |
| Celularity Inc. | 143.88 Million USD | -2168.816% |
| Rallybio Corporation | 115.62 Million USD | -2723.539% |
| Cue Biopharma, Inc. | 61.53 Million USD | -5205.666% |
| MeiraGTx Holdings plc | 458.16 Million USD | -612.528% |
| Omeros Corporation | 378.26 Million USD | -763.03% |
| Humacyte, Inc. | 128.22 Million USD | -2446.014% |
| Immunocore Holdings plc | 597 Million USD | -446.829% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -10343.635% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -4663.718% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -211.134% |
| CalciMedica, Inc. | 12.18 Million USD | -26691.76% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -1187.04% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -1810.136% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -949.585% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -477.495% |
| Pulmatrix, Inc. | 33.95 Million USD | -9513.57% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -11925.993% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -2217.636% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -150.933% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -2407.566% |
| Cytokinetics, Incorporated | 824.31 Million USD | -296.035% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -15355.077% |
| Nutriband Inc. | 7.51 Million USD | -43328.351% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -4034.782% |
| Vor Biopharma Inc. | 209.82 Million USD | -1455.834% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 54.8% |
| Evogene Ltd. | 51.1 Million USD | -6288.478% |
| ProKidney Corp. | 420.55 Million USD | -676.26% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -5853.67% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -34190.763% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -497.492% |
| CorMedix Inc. | 82.05 Million USD | -3878.281% |
| BioLineRx Ltd. | 63.92 Million USD | -5006.885% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -710.94% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -11476.511% |
| Atai Life Sciences N.V. | 293.47 Million USD | -1012.375% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -1901.218% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -2462.1% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -480.858% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -3275.32% |
| MediciNova, Inc. | 66.26 Million USD | -4826.176% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -3611.939% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -73057.978% |
| GeoVax Labs, Inc. | 9.28 Million USD | -35066.422% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -454.977% |
| Biomea Fusion, Inc. | 199.92 Million USD | -1532.884% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | -71.533% |
| Mereo BioPharma Group plc | 66.49 Million USD | -4809.211% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -572.975% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -432.662% |
| Absci Corporation | 234.48 Million USD | -1292.262% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -44528.517% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -860.477% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -1877.548% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -520.262% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -1075.606% |
| Allakos Inc. | 243.61 Million USD | -1240.083% |
| Imunon, Inc. | 21.91 Million USD | -14794.451% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -1166.842% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -425.259% |
| BioAtla, Inc. | 119.65 Million USD | -2628.256% |
| NLS Pharmaceutics AG | 1.84 Million USD | -176684.551% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -101284.348% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -407.839% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -3302.904% |
| XOMA Corporation | 234.3 Million USD | -1293.326% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -1375.615% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -2494.145% |
| aTyr Pharma, Inc. | 122.06 Million USD | -2574.413% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -2021.191% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -462.595% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -565.664% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -2855.196% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -21437.61% |
| Akari Therapeutics, Plc | 4.35 Million USD | -74861.561% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -19061.309% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -88.348% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -105755.733% |
| UroGen Pharma Ltd. | 178.31 Million USD | -1730.833% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -593.505% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -587355.08% |
| Orgenesis Inc. | 14.55 Million USD | -22333.865% |
| Entera Bio Ltd. | 11.76 Million USD | -27648.202% |
| GH Research PLC | 226.3 Million USD | -1342.588% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -5868.801% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -2938.624% |
| Xencor, Inc. | 952.69 Million USD | -242.669% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -41840.802% |
| Replimune Group, Inc. | 487.72 Million USD | -569.352% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -40347.776% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -403.451% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -105755.733% |
| Portage Biotech Inc. | 7.77 Million USD | -41866.525% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -73057.978% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -1078.781% |
| OncoCyte Corporation | 74.89 Million USD | -4259.045% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -160459.656% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -56315.715% |
| Purple Biotech Ltd. | 44.3 Million USD | -7268.913% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -9466.243% |
| scPharmaceuticals Inc. | 94.47 Million USD | -3355.346% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -17991.347% |
| HilleVax, Inc. | 344.43 Million USD | -847.809% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -102688.917% |
| Tharimmune, Inc. | 10.94 Million USD | -29723.303% |
| Genprex, Inc. | 10.67 Million USD | -30494.141% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -557.922% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -3291.697% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -134466.2% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -78272.878% |
| OKYO Pharma Limited | 1.54 Million USD | -211711.604% |
| Savara Inc. | 177.56 Million USD | -1738.535% |
| Curis, Inc. | 77.28 Million USD | -4124.239% |
| Daré Bioscience, Inc. | 21.28 Million USD | -15239.456% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -5004.984% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -40273.188% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -16752.904% |
| BeiGene, Ltd. | 5.8 Billion USD | 43.765% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -26726.987% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | -56.305% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -812.018% |
| Erasca, Inc. | 395.29 Million USD | -725.854% |
| bluebird bio, Inc. | 619.16 Million USD | -427.258% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -75410.002% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 52.283% |
| DBV Technologies S.A. | 182.98 Million USD | -1684.058% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -75410.002% |
| Moderna, Inc. | 18.42 Billion USD | 82.283% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -17820.492% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -28076.903% |
| Molecular Templates, Inc. | 35.38 Million USD | -9126.397% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -2261.101% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -313.807% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -974.74% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -3040.646% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -601.114% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -941.541% |
| MacroGenics, Inc. | 306.82 Million USD | -964.004% |
| RenovoRx, Inc. | 1.46 Million USD | -222585.948% |
| Adicet Bio, Inc. | 207.29 Million USD | -1474.846% |
| Prime Medicine, Inc. | 193.85 Million USD | -1584.065% |
| Aditxt, Inc. | 44.57 Million USD | -7223.236% |
| Adagene Inc. | 115.72 Million USD | -2720.884% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -73192.265% |
| Quantum-Si incorporated | 298.25 Million USD | -994.577% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | -119.475% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -42246.918% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -829.335% |
| SciSparc Ltd. | 11.18 Million USD | -29094.92% |
| Vericel Corporation | 353.65 Million USD | -823.091% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -26631.192% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -5637.33% |
| Generation Bio Co. | 374.75 Million USD | -771.116% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -1181.905% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -1958.799% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -856.33% |
| Invivyd, Inc. | 229.18 Million USD | -1324.453% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -286.807% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -26726.323% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -1689.888% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -15884.019% |
| 2seventy bio, Inc. | 565.42 Million USD | -477.366% |
| ADMA Biologics, Inc. | 329.18 Million USD | -891.724% |
| Clene Inc. | 52.34 Million USD | -6137.13% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -5458.208% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -2413.262% |
| GeoVax Labs, Inc. | 9.28 Million USD | -35066.422% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -399.4% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -3050.796% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -2403.778% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -3246.497% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -4498.189% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -1245.923% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | -66.552% |
| Evaxion Biotech A/S | 12.88 Million USD | -25229.137% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -1195.158% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -333.722% |
| Trevena, Inc. | 40.6 Million USD | -7939.837% |
| Surrozen, Inc. | 46.08 Million USD | -6984.583% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -1345.417% |
| Cingulate Inc. | 3.49 Million USD | -93402.387% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -19531.824% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -4869.67% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -27839.069% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -1115.78% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -335.884% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -2493.156% |
| Clearmind Medicine Inc. | 4.32 Million USD | -75392.191% |
| Kronos Bio, Inc. | 213.27 Million USD | -1430.66% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -1943.118% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -38034.853% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -785.933% |
| Statera Biopharma, Inc. | 21.16 Million USD | -15320.995% |
| ImmunityBio, Inc. | 504.45 Million USD | -547.153% |
| Korro Bio, Inc. | 221.66 Million USD | -1372.765% |
| Kineta, Inc. | 10.28 Million USD | -31653.487% |
| BioVie Inc. | 25.2 Million USD | -12850.378% |
| Codexis, Inc. | 136.56 Million USD | -2290.562% |
| Celularity Inc. | 143.88 Million USD | -2168.816% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -413.821% |
| Celcuity Inc. | 191.21 Million USD | -1607.241% |
| Virax Biolabs Group Limited | 5.48 Million USD | -59429.439% |
| Cibus, Inc. | 544.41 Million USD | -499.653% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -2493.115% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -15790.654% |
| IN8bio, Inc. | 33.7 Million USD | -9584.583% |
| Kodiak Sciences Inc. | 479.37 Million USD | -581.011% |
| Annexon, Inc. | 297.67 Million USD | -996.695% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -1786.929% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -2274.772% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -15450.784% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -9.181% |
| Eyenovia, Inc. | 28.77 Million USD | -11243.457% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -1316.13% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -45090.698% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -5258.264% |
| Arcellx, Inc. | 825.13 Million USD | -295.643% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -3898.893% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -606.198% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -10516.507% |
| Moolec Science SA | 24.05 Million USD | -13473.393% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -952.665% |
| Geron Corporation | 394.07 Million USD | -728.413% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -3109.69% |
| Royalty Pharma plc | 16.38 Billion USD | 80.072% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -448.698% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -46571.37% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -27043.013% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -1344.119% |
| Humacyte, Inc. | 128.22 Million USD | -2446.014% |
| Structure Therapeutics Inc. | 482.01 Million USD | -577.274% |
| 89bio, Inc. | 596.26 Million USD | -447.501% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -1194.686% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -176363.568% |
| Genelux Corporation | 27.89 Million USD | -11603.926% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -3551.528% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -1322.913% |
| Notable Labs, Ltd. | 19.54 Million USD | -16606.289% |
| Liquidia Corporation | 120.43 Million USD | -2610.744% |
| Mustang Bio, Inc. | 17.74 Million USD | -18300.271% |
| Immunovant, Inc. | 666.71 Million USD | -389.653% |
| Quantum-Si incorporated | 298.25 Million USD | -994.577% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -2160.771% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -5927.651% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -1759.67% |
| Acasti Pharma Inc. | 73.3 Million USD | -4353.719% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -71612.972% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -12399.88% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | -238.369% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -62802.266% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -14230.258% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -6226.33% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -1706.718% |
| PepGen Inc. | 143.05 Million USD | -2182.09% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -8442.209% |
| United Therapeutics Corporation | 7.16 Billion USD | 54.45% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -16916.294% |
| Solid Biosciences Inc. | 164.93 Million USD | -1879.263% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -55493.169% |
| Immuneering Corporation | 102.58 Million USD | -3082.328% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -75668.483% |
| Silo Pharma, Inc. | 7.74 Million USD | -42044.547% |
| Belite Bio, Inc | 94.64 Million USD | -3349.395% |
| XOMA Corporation | 234.3 Million USD | -1293.326% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -1299.976% |
| Bionomics Limited | 27.64 Million USD | -11707.172% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -713.289% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -2939.982% |
| uniQure N.V. | 831.68 Million USD | -292.524% |
| Cassava Sciences, Inc. | 151.66 Million USD | -2052.52% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -73192.265% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -1091.951% |
| Forte Biosciences, Inc. | 38.98 Million USD | -8275.003% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -80049.389% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -8763.664% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -45090.698% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -92828.437% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -27516.75% |
| Altimmune, Inc. | 210.64 Million USD | -1449.837% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -319.676% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -2939.982% |
| Compugen Ltd. | 121.33 Million USD | -2590.57% |
| Peak Bio, Inc. | 2.59 Million USD | -125633.983% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -1794.408% |
| Benitec Biopharma Inc. | 52.21 Million USD | -6152.779% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -854.948% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -9288.25% |
| Zura Bio Limited | 100.84 Million USD | -3137.286% |
| PolyPid Ltd. | 15.37 Million USD | -21137.158% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -2636.764% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -9288.25% |
| Instil Bio, Inc. | 325.63 Million USD | -902.542% |
| argenx SE | 4.54 Billion USD | 28.132% |
| Immunome, Inc. | 148.54 Million USD | -2097.776% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -1981.005% |
| Verona Pharma plc | 308.12 Million USD | -959.501% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -3654.155% |
| Shattuck Labs, Inc. | 159.56 Million USD | -1945.935% |
| CervoMed Inc. | 9.97 Million USD | -32635.714% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -1632.275% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -28566.807% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -1719.668% |
| Moolec Science SA | 24.05 Million USD | -13473.393% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -53264.719% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -1787.645% |
| AnaptysBio, Inc. | 452.38 Million USD | -621.63% |
| Design Therapeutics, Inc. | 289.64 Million USD | -1027.103% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -4382.768% |
| NeurAxis, Inc. | 509.49 Thousand USD | -640643.634% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -60154.264% |
| Lumos Pharma, Inc. | 40.63 Million USD | -7933.309% |
| Achilles Therapeutics plc | 161.45 Million USD | -1921.96% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -3654.155% |
| 180 Life Sciences Corp. | 5.25 Million USD | -61970.366% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -4535.352% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -38034.853% |
| Nutriband Inc. | 7.51 Million USD | -43328.351% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -1181.804% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -1538.013% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -4183.546% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -5536.743% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -520.005% |
| Palisade Bio, Inc. | 14.05 Million USD | -23132.109% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -1452.379% |
| Beam Therapeutics Inc. | 1.45 Billion USD | -123.645% |
| Neurogene Inc. | 222.57 Million USD | -1366.744% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -404.867% |
| AEON Biopharma, Inc. | 6.84 Million USD | -47592.856% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -620.6% |
| Sesen Bio, Inc. | 189.17 Million USD | -1625.7% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -1100.799% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -23708.394% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -318.347% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -1122.715% |
| Athira Pharma, Inc. | 160.24 Million USD | -1937.24% |
| Vaccinex, Inc. | 3.63 Million USD | -89808.455% |
| HCW Biologics Inc. | 28.51 Million USD | -11349.165% |
| XOMA Corporation | 234.3 Million USD | -1293.326% |
| Nektar Therapeutics | 398.03 Million USD | -720.177% |
| Arvinas, Inc. | 1.3 Billion USD | -150.236% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -19061.309% |
| Merus N.V. | 458.49 Million USD | -612.022% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -1497.416% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -1711.6% |
| Rezolute, Inc. | 132.73 Million USD | -2359.432% |
| Clene Inc. | 52.34 Million USD | -6137.13% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -21774.85% |
| BeyondSpring Inc. | 24.8 Million USD | -13059.368% |
| Synlogic, Inc. | 75.55 Million USD | -4221.08% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -27421.295% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -34763.05% |
| Peak Bio, Inc. | 2.59 Million USD | -125633.983% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -1767.254% |
| Krystal Biotech, Inc. | 818.35 Million USD | -298.919% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -1257.762% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -349.797% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -91161.314% |
| MannKind Corporation | 475.19 Million USD | -586.993% |
| Ikena Oncology, Inc. | 192.09 Million USD | -1599.486% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -24309.87% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -2701.273% |
| Gossamer Bio, Inc. | 311.91 Million USD | -946.62% |
| CohBar, Inc. | 16.36 Million USD | -19847.711% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -9184.123% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -44528.517% |
| Legend Biotech Corporation | 1.84 Billion USD | -76.596% |
| Mural Oncology plc | 301.74 Million USD | -981.899% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -10358.357% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -57370.832% |
| Disc Medicine, Inc. | 367.99 Million USD | -787.123% |
| Champions Oncology, Inc. | 26.13 Million USD | -12392.637% |
| REGENXBIO Inc. | 573.97 Million USD | -468.771% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -120449.244% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -2014.554% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -26934.528% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -860.071% |
| Vaxart, Inc. | 91.83 Million USD | -3455.021% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -5349.69% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -2100.933% |
| Cellectis S.A. | 334.27 Million USD | -876.628% |
| Longeveron Inc. | 12.17 Million USD | -26707.16% |
| Repare Therapeutics Inc. | 253.9 Million USD | -1185.767% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -1525.404% |
| Revolution Medicines, Inc. | 2.08 Billion USD | -56.305% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -200796.985% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -1075.53% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -1901.604% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -2252.949% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -12691.223% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 85.638% |
| Denali Therapeutics Inc. | 1.15 Billion USD | -182.913% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -26631.192% |
| Veru Inc. | 50.59 Million USD | -6352.251% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -7066.544% |
| Cingulate Inc. | 3.49 Million USD | -93402.387% |
| Passage Bio, Inc. | 150.54 Million USD | -2068.505% |
| Context Therapeutics Inc. | 16.06 Million USD | -20223.911% |
| Exicure, Inc. | 11.58 Million USD | -28091.503% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -768.127% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -1919.634% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -18584.615% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -881.104% |
| Nuvalent, Inc. | 732.38 Million USD | -345.746% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -21745.281% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -3545.372% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -22904.552% |
| OmniAb, Inc. | 401.98 Million USD | -712.114% |
| Anew Medical, Inc. | 19.45 Million USD | -16679.317% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -12114.728% |
| Lipocine Inc. | 23 Million USD | -14093.147% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -2235.059% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -968.374% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -3789.12% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -2586.01% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -41041.474% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -270.017% |
| Ocugen, Inc. | 64.54 Million USD | -4957.673% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -2521.286% |
| Q32 Bio Inc. | 306.11 Million USD | -966.44% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -77480.228% |
| Alumis Inc. Common Stock | 89.61 Million USD | -3543.012% |
| Equillium, Inc. | 50.53 Million USD | -6360.669% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -4241.48% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -7809.613% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -191837.575% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -12388.336% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -4965.992% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -87489.939% |
| Dominari Holdings Inc. | 57.55 Million USD | -5571.802% |
| Edesa Biotech, Inc. | 8.89 Million USD | -36620.085% |
| vTv Therapeutics Inc. | 11.01 Million USD | -29529.479% |
| Bio-Techne Corporation | 2.81 Billion USD | -16.045% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -248.363% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -302.315% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -1075.725% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -7728.344% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -389.011% |
| Nkarta, Inc. | 378.88 Million USD | -761.627% |
| BioCardia, Inc. | 2.98 Million USD | -109192.802% |
| Iterum Therapeutics plc | 26.25 Million USD | -12332.218% |